tbuckley/cabot-search huggingface dataset:
The Novel Proteasome Inhibitor NPI-0052 Induces the Expression of Raf-1 Kinase Inhibitor Protein RKIP) in B-NHL via Inhibition of the Transcription Repressor Snail: Roles of Snail and RKIP in Sensitization to TRAIL Apoptosis
Authors: Stavroula Baritaki, Aaron Chapman, Katherine Wu, Kam Yeung, Demetrios Spandidos, James R. Berenson, Michael A. Palladino, Benjamin Bonavida
Journal: Blood (2008)
Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: A population-based study
Authors: W.P.M. Dijksterhuis, R.H.A. Verhoeven, M. Slingerland, N. Haj Mohammad, J. de Vos-Geelen, L.V. Beerepoot, T. Van Voorthuizen, G.-J. Creemers, M. van Oijen, H.W.M. van Laarhoven
Journal: Annals of Oncology (2019)
Potential Liability for Physicians Using Artificial Intelligence
Authors: W. Nicholson Price, Sara Gerke, I. Glenn Cohen
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)
Authors: T.M. Kim, C.-Y. Ock, M. Kim, S.H. Kim, B. Keam, Y.J. Kim, D.-W. Kim, J.-S. Lee, D.S. Heo
Journal: Annals of Oncology (2019)
DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Authors: S. Trudel, A. Nooka, D. Fecteau, M. Talekar, R.C. Jewell, D. Williams, J. Evans, J. Opalinska
Journal: Annals of Oncology (2019)
Distribution of human leucocyte antigens in children with solid malignant tumors.
Authors: Tatiana V. Fadeeva, Yuliya Yu. Kozel, Ella E. Kudinova, Sergei A. Kuznetsov, Maria V. Starzhetskaya, Gulnara A. Mkrtchyan
Journal: Journal of Clinical Oncology (2014)

e21014 Background: It is considered nowadays that any disease results from the interaction of environmental factors and genetic ones. Among the latter, HLA system has figured prominently recently, studying of associative relations between tumors and HLAs has become more interesting for researchers. These studies are important for early diagnosis of cancer. The purpose of our study was to analyze distribution of HLA class I (A, B) and II (DRB1*) antigens in children and adolescents with solid malignant tumors. Methods: Data on 113 patients (pts) with different solid malignancies were studied: 21 pts with neuroblastoma (18,6%), 21 with nephroblastoma (18,6%), 20 with osteosarcoma (17,7%), 20 with Ewing's sarcoma (17,7%), 31 with germ cell tumor (27,4%). Identification of HLA class I antigens was made with serologic method with the use of standardized serum set. Molecular typing of HLA class II antigens was made with PCR-SSP method. χ2 criterion with Yates' correction for continuity was used for assessment of significance of differences. Results: The analysis of typing of children with solid tumors, as compared to the group of healthy donors, showed significant increase of frequency of the following HLAs: A26 – 20% (the control 5,35%) (p<0,02), B51 – 30% (the control – 12,35%) (p<0,05) – in Ewing's sarcoma; A24 – 38,09% (the control 16,46%) (p<0,02), B13 – 38,09% (control – 11,6%) (p<0,01), DRB 1*04 – 42,85% (the control – 18,75%) (p<0,05) – in neuroblastoma; DRB1*13 – 57,14% (the control – 29,68%) (p<0,05) – in nephroblastoma; A26 – 16,12% (the control – 5,35%) (p<0,05) – in germ cell tumor. Conclusions: Thus, when identifying certain alleles in a genotype, children should be considered as patients of groups at risk of Ewing's sarcoma (A26,51), neuroblastoma (A24, B13, B44, DRBI*04), nephroblastoma (DRBI*13) and germ cell tumor (A26).
Pan-cancer whole genome analyses of metastatic solid tumors
Authors: E. Cuppen, P. Priestley, J. Baber, M.P. Lolkema, N. Steeghs, E. de Bruijn, K. Duyvesteyn, S. Haidari, A. van Hoeck, P. Roepman, C. Shale, M. Voda, V.C.G. Tjan-Heijnen, H. Bloemendal, C. van Herpen, M. Labots, P.O. Witteveen, E.F. Smit, S. Sleijfer, E.E. Voest
Journal: Annals of Oncology (2019)
Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience
Authors: S. Aksoy, R.F. Degirmenciler, B.Y. Aktas, D.C. Guven, O.H. Aktepe, G. Guner, H. Taban, N. Kertmen, Z. Arik, O. Dizdar
Journal: Annals of Oncology (2019)
Predicting complications of chemotherapy-induced febrile neutropenia: A single-center experience.
Authors: Bharatsinha Baburao Bhosale, Vijay Patil, Vamshi Muddu, Randeep Singh, Pankaj Dwivedi, Vanita Noronha, Amit Joshi, Jaya Ghosh, Sudeep Gupta, Shripad Banavali, Kumar Prabhash
Journal: Journal of Clinical Oncology (2013)

e20678 Background: Identifying the parameters associated with increased complications would help to formulate a cost-effective and rational therapy in patients with chemotherapy induced febrile neutropenia. Methods: We prospectively collected data from January 2007-December 2011 of consecutive episodes of neutropenic fever at our centre. Clinical features, laboratory characteristics and MASCC score were analysed to identify patients at higher risk for developing complications. Complications were defined as either of the following event: failure of first line antibiotics, organ failure, delay in next cycle of chemotherapy, inpatient admission and death. Results: Three hundred and eighty-eight febrile neutropenia (FN) episodes in 373 patients were included, 256 episodes of FN in hematolymphoid malignancies and 132 episodes of FN in solid tumours. The median age was 31 years (11-76 years). Two hundred and forty-four (65.4%) patients were male. One hundred forty-nine patients (39.94%) had FN during previous cycles, while primary GCSF prophylaxis was used for 205 (52.84%) cases. The median haemoglobin, nadir neutrophil count &amp; median number of days with severe neutropenia (&lt; 1X10 9 /L) were 7.9 gm/dl, 0.04X10 9 /L and 4 days respectively. A clinical focus of infection was present in 174 (44.8%) episodes, with gastrointestinal being the commonest in 70episodes (40.23%). High risk MASCC score (&lt;21) was present in 156 episodes (40%). Complications were seen in 133(34%) instances. On Univariate analysis, age, type of malignancy, prophylactic growth factor use, clinical focus of infection, day of FN, MASCC score, nadir Hb and platelet count were significantly associated with complications. All predictive factors except age and nadir Hb could independently predict complication on multivariate analysis. Conclusions: Clinical and laboratory parameters in addition to MASCC score could help in identifying patients with FN who require hospitalisation and more intensive management strategies.
SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Results from the phase I part of a phase I/II trial
Authors: A. Digklia, C. Britschgi, Y. Metaxas, A. Kollar, F. Krasniqi, A. Stathis, T. Rordorf, I. Colombo, N. Mach, S. Hofer, M. Montemurro, N. Stojcheva, D. Dietrich, C.A. Rothermundt
Journal: Annals of Oncology (2019)
Cell-Free DNA to detect focal versus non-focal MET amplification in metastatic colorectal cancer patients: Combined analysis from Japan and the United States
Authors: M. Saori, A. Kawazoe, Y. Nakamura, J.I. Odegaard, M.I. Lefterova, R. Lanman, T. Yoshino, J.H. Strickler
Journal: Annals of Oncology (2019)
Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Authors: Y. Miura, K. Kodaira, M. Kenmochi, T. Yamashiro, O. Yamaguchi, A. Shiono, A. Mouri, F. Nishihara, S. Shinomiya, K. Hashimoto, Y. Murayama, K. Kobayashi, K. Kaira, H. Kagamu
Journal: Annals of Oncology (2019)
Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery
Authors: Da Sun, Jia Chen, Yuan Wang, Hao Ji, Renyi Peng, Libo Jin, Wei Wu
Journal: Theranostics (2019)

Cancer remains a daunting and cureless disease, which is responsible for one-sixth of human deaths worldwide.These mortality rates have been expected to rise in the future due to the side effects of conventional treatments (chemotherapy, radiotherapy, and surgery), which can be addressed by applying nanomedicine.In order to escape from biological barriers, such nanomedicine should be mimicked and designed to be stealthy while navigating in the bloodstream.To achieve this, scientists take advantage of erythrocytes (red blood cells; RBCs) as drug carriers and develop RBC membrane (RBCm) coating nanotechnology.Thanks to the significant advances in nanoengineering, various facile surface functionalization methods can be applied to arm RBCm with not only targeting moieties, but also imaging agents, therapeutic agents, and nanoparticles, which are useful for theranostic nanomedicine.This review focuses on refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
Multicenter randomized phase II trial of 5-fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
Authors: C. Yoo, J.H. Jeong, K.-P. Kim, J. Cheon, I. Kim, M. Kang, H. Ryu, B.W. Kang, B.-Y. Ryoo
Journal: Annals of Oncology (2019)
GW29-e1780 Acacetin inhibits the apoptosis induced by lysophosphatidylcholine via activating Nrf2 in cultured rat aortic vascular smooth muscle cells
Authors: Yunda Li, Weiyin Wu, Yao Wu, Gang Li, Lingjun Jie, Guirong Li, Yan Wang
Journal: Journal of the American College of Cardiology (2018)
Breast cancer statistics, 2019
Authors: Carol E. DeSantis, Jiemin Ma, Mia M. Gaudet, Lisa A. Newman, Kimberly D. Miller, Ann Goding Sauer, Ahmedin Jemal, Rebecca L. Siegel
Journal: CA A Cancer Journal for Clinicians (2019)

Abstract This article is the American Cancer Society’s biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5‐year period (2012‐2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor‐positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black–white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged &lt;50 years, who have a death rate double that of whites. In the most recent 5‐year period (2013‐2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016‐2017. Declines in breast cancer mortality could be accelerated by expanding access to high‐quality prevention, early detection, and treatment services to all women.
Abstract 17593: Long-term Clinical Follow-up Results of Patients With Apical Hypertrophic Cardiomyopathy
Authors: Yong-Hoon Yoon, Sang Yong Om, Jeong Yoon Jang, Byung Joo Sun, Dae Hee Kim, Jong-Min Song, Duk-Hyun Kang, Jae-Kwan Song
Journal: Circulation (2013)

Background: Apical hypertrophic cardiomyopathy (AHC) is relatively common in the Asian countries and there have been limited data about the long-term clinical course of disease. Methods: The study ...
Thymic Function Predicts Response to Mesenchymal Stromal Cell Treatment in Chronic GvHD: A Phase II Clinical Study
Authors: Erik Boberg, Lena Von Bahr, Nina Heldring, Gabriel Afram, Ellen Iacobaeus, Carina Lindström, Karin Garming-Legert, Per Ljungman, Rachael Sugars, Lindsay Davies, Nadir Kadri, Katarina Le Blanc
Journal: Blood (2017)
Translation of <i>in vitro</i> findings to patients with asthma: a timely and compelling challenge
Authors: Pieter S. Hiemstra, Peter J. Sterk
Journal: European Respiratory Journal (2019)

<b>This editorial discusses the value of various approaches and models to study asthma, and the need for an open-minded dialogue between basic, translational and clinical scientists to discuss potential discrepancies between findings in the various models.</b>http://bit.ly/2m5ZvJo
Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas
Authors: Samer A. Srour, Issa F. Khouri, Sara Lozano-Cerrada, Yago Nieto, Amin M. Alousi, Uday R. Popat, Muzaffar H. Qazilbash, Paolo Anderlini, Partow Kebriaei, Elizabeth J. Shpall, Richard E. Champlin, Chitra Hosing
Journal: Blood (2016)
EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains
Authors: Wendy Béguelin, Matt R. Teater, Katerina Hatzi, Relja Popovich, Yanwen Jiang, Karen L. Bunting, Monica Rosen, Hao Shen, Shao Ning Yang, Young Rock Chung, Rita Shaknovich, Caretha Creasy, Randy D. Gascoyne, Leandro Cerchietti, Ross L. Levine, Omar Abdel-Wahab, Jonathan D. Licht, Olivier Elemento, Ari M. Melnick
Journal: Blood (2013)
Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia
Authors: Christopher A. Eide, Samantha L. Savage, Michael C. Heinrich, Anna M. Reister Schultz, Jeffrey W. Tyner, Cristina E. Tognon, Brian J. Druker
Journal: Blood (2016)
A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload
Authors: Hugh Y. Rienhoff, ip Viprakasit, Lay H. Tay, Paul Harmatz, Elliott Vichinsky, Deborah Chirnomas, Janet Kwiatkowski, Amy E Tapper, John B Porter, Ellis J. Neufeld
Journal: Blood (2010)
BH3 Profiling Predicts 5-Azacytidine Response in Malignant Myeloid Cells
Authors: James M Bogenberger, William E. Pierceall, Ryan Lena, Reinhold Munker, Kaoru Tohyama, Lisa Sproat, Pierre Noel, Jose F. Leis, James L Slack, Ruben A. Mesa, Michael Cardone, Raoul Tibes
Journal: Blood (2012)
Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells
Authors: Diana Cirstea, Teru Hideshima, Loredana Santo, Samantha Pozzi, Sonia Vallet, Kishan Patel, Gullu Gorgun, Yiguo Hu, Sylvie M Guichard, Anuj Mahindra, Kenneth C. Anderson, Noopur Raje
Journal: Blood (2010)
Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder
Authors: James Dugan, Bradley M. Haverkos, Ludmila Katherine Martin, Marisa F. Martin, Mark E Lustberg, John T. Patton, Gerard Nuovo, Fengting Yan, Robert Cavaliere, Shannon C. Kenney, Joyce Fingeroth, Gerard Lozanski, Juan Carlos Ramos, Pierluigi Porcu, Michael A. Caligiuri, Robert A. Baiocchi
Journal: Blood (2014)
RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program
Authors: Ly P. Vu, Camila Prieto, Elianna Amin, Gerard Minuesa, Sagar Chhangawala, Maria J Vidal, Andrei V. Krivtsov, Tim Chou, Trevor Barlowe, James Taggart, Patrick Tivnan, Raquel P. Deering, Mithat Gonen, Maria E Figueroa, Elisabeth Paietta, Martin S. Tallman, Ari Melnick, Ross L. Levine, Fatima Al-Shahrour, Marcus Järås, Lisa Chu, Ralph Garippa, Christopher Lengner, Scott A. Armstrong, Glenn Cowley, David Root, John G Doench, Leandro Cerchietti, Christina Leslie, Benjamin Ebert, Michael G. Kharas
Journal: Blood (2016)
Review: In older adults with acute major depression, SNRIs, but not SSRIs, increase adverse events vs placebo
Authors: Gregory Simon
Journal: Annals of Internal Medicine (2019)

Source Citation Sobieraj DM, Martinez BK, Hernandez AV, et al. Adverse effects of pharmacologic treatments of major depression in older adults. J Am Geriatr Soc. 2019;67:1571-81. 31140587
Oligoclonal Expansion of Vδ1+ γδT Cells in Cyclosporine-Responsive Acquired Pure Red Cell Aplasia.
Authors: Makoto Hirokawa, Naohito Fujishima, Yuhta Oyama, Masumi Fujishima, Takahiro Horiuchi, Atsushi Kitabayashi, Ikuo Miura, Ken-ichi Sawada
Journal: Blood (2004)
Bortezomib, Doxorubicin and Dexamethasone (PAD) Prior to High-Dose Melphalan / Autologous Stem Cell Transplantation for Newly Diagnosed Plasma Cell Dycrasias.
Authors: Delphine Lebon, Berengere Gruson, Reda Garidi, Jean Luc Dutel, Corinne Thevenot, Bachra Choufi, Kamel Ghomary, Brigitte Kolb, Isabelle Leduc, Ioana Vaida, Gandhi Damaj, Jean Pierre Marolleau, Bruno Royer
Journal: Blood (2009)
Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development
Authors: Dimitrios C. Mastellos, Anna M. Blom, E. Sander Connolly, Mohamed R. Daha, Brian V. Geisbrecht, Berhane Ghebrehiwet, Piet Gros, George Hajishengallis, V. Michael Holers, Markus Huber-Lang, Taroh Kinoshita, Tom E. Mollnes, Robert A. Montgomery, B. Paul Morgan, Bo Nilsson, Ruben Pio, Daniel Ricklin, Antonio M. Risitano, Ronald P. Taylor, Alberto Mantovani, John P. A. Ioannidis, John D. Lambris
Journal: Nature Immunology (2019)
Somatic Gene Therapy for X-Linked Severe Combined Immunodeficiency Using a Self-Inactivating Modified Gammaretroviral Vector Results in An Improved Preclinical Safety Profile and Early Clinical Efficacy in a Human Patient
Authors: Sung-Yun Pai, Luigi Daniele Notarangelo, Chad Harris, Federica Cattaneo, Matthew Wladkowski, Myriam Armant, Grace S. Kao, Matthew Wielgosz, Arthur W. Nienhuis, Ute Modlich, Martijn Brugman, Axel Schambach, Michael Rothe, Susannah I Thornhill, H. Bobby Gaspar, Kathryn Parsley, Samantha Cooray, Elke Grassman, Frederic Bushman, Sally Shupien, Matias Oleastro, Salima Hacein-Bey-Abina, Alain Fischer, Marina Cavazzana-Calvo, Punam Malik, Alexandra Filipovich, Donald B. Kohn, Christopher Baum, David A. Williams, Adrian J Thrasher
Journal: Blood (2011)
Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.
Authors: Cornelia Becker, Haifa Al Ali, Rainer Krahl, Wolfram Poenisch, Dirk Hasenclever, Luisa Mantovani, Mathias Freund, R. Subert, Ute Hegenbart, Ulrich Wedding, Johannes Meran, Michael Herold, Norma Peter, W. Knauf, Erika Kettner, T. Ittel, Astrid Franke, K. Dachselt, H.H. Wolf, Ute Kreibich, Manfred Schulze, Michael Assmann, Norbert Grobe, Renate Huhn, Ernst Zschuppe, Veronika Schirmer, U. Haak, C. Klinkenstein, B. Opitz, Rita Pasold, F. Fiedler, C. Winkelmann, Werner Helbig, Dietger Niederwieser
Journal: Blood (2005)
Semi-automated medulloblastoma segmentation and influence of molecular subgroup on segmentation quality
Authors: Richard Dury, Rob Dineen, Anbarasu Lourdusamy, Richard Grundy
Journal: Neuro-Oncology (2019)

Abstract Medulloblastoma is the most common malignant brain tumour in children. Segmenting the tumour itself from the surrounding tissue on MRI scans has shown to be useful for neuro-surgical planning, by allowing a better understanding of the tumour margin with 3D visualisation. However, manual segmentation of medulloblastoma is time consuming, prone to bias and inter-observer discrepancies. Here we propose a semi-automatic patient based segmentation pipeline with little sensitivity to tumour location and minimal user input. Using SPM12 “Segment” as a base, an additional tissue component describing the medulloblastoma is included in the algorithm. The user is required to define the centre of mass and a single surface point of the tumour, creating an approximate enclosing sphere. The calculated volume is confined to the cerebellum to minimise misclassification of other intracranial structures. This process typically takes 5 minutes from start to finish. This method was applied to 97 T2-weighted scans of paediatric medulloblastoma (7 WNT, 6 SHH, 17 Gr3, 26 Gr4, 41 unknown subtype); resulting segmented volumes were compared to manual segmentations. An average Dice coefficient of 0.85±0.07 was found, with the Group 4 subtype demonstrating a significantly higher similarity with manual segmentation than other subgroups (0.88±0.04). When visually assessing the 10 cases with the lowest Dice coefficients, it was found that the misclassification of oedema was the most common source of error. As this method is independent of image contrast, segmentation could be improved by applying it to images that are less sensitive to oedema, such as T1.
High Prognostic Value of a 3-Genes Molecular Score in Non-High Risk Acute Promyelocytic Leukemia Treated with AIDA 2000 Protocol: A Retrospective Study from a Regional Register
Authors: Guardo Daniela, Fabio Guolo, Paola Minetto, Marino Clavio, Livia Giannoni, Elisa Coviello, Giordana Pastori, Giulia Rivoli, Filippo Ballerini, Nicoletta Colombo, Raffaella Grasso, Maurizio Miglino, Roberto Massimo Lemoli, Marco Gobbi
Journal: Blood (2015)
Platelet Activation Promotes Formation of Platelet-Leukocyte Conjugates (PLC) in Non-Valvular Atrial Fibrillation (AF).
Authors: Aurelio Castrellon, Julio A. Chirinos, Juan P. Zambrano, Wenche Jy, Lawrence L. Horstmann, Eugene R. Ahn, Joaquin J. Jimenez, Howard Willens, Agustin Castellanos, Robert J. Myerburg, Yeon S. Ahn
Journal: Blood (2004)
Pharmacokinetics of Anti-CD22 Antibody Conjugates with Uncleavable and Cleavable Linkers in Rats.
Authors: Dong Xie, Rong Deng, Jakub Baudys, Pam Chan, Randy Dere, Allen Ebens, Paul Fielder, Reina Fuji, Alane Gray, Catherine Hung, Suhas Iyer, Kathleen McKeever, Margaret Kenrick, Will Leach, Andrew Polson, Ola Saad, Jean-Philippe Stephan, Ben Quan Shen, Jay Tibbitts, Shang-Fan Yu, Saileta Prabhu
Journal: Blood (2007)
Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a,
Authors: Harini Nivarthi, Andriy Tsyrulnyk, Wolfgang Warsch, Zhengqi Wang, Susanne Winkler, Lukas Kenner, Mathias Müller, Christopher Baum, Kevin D. Bunting, Veronika Sexl, Thomas Rülicke, Richard Moriggl
Journal: Blood (2011)
Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues
Authors: David W. Scott, George W. Wright, Mickey Williams, Jason Lih, Elaine S. Jaffe, Andreas Rosenwald, Elias Campo, Wing (John) C Chan, Joseph M. Connors, Erlend Smeland, Rita M. Braziel, German Ott, Jan Delabie, Dennis D. Weisenburger, James R. Cook, Timothy C. Greiner, Kai Fu, William Walsh, Randy D. Gascoyne, Louis M. Staudt, Lisa M. Rimsza
Journal: Blood (2014)